|
TODAY'S HEADLINES
A phase 3 study evaluating the efficacy and safety of biosimilar candidate ABP 501 compared with Humira (adalimumab, AbbVie) in treating plaque psoriasis has met its primary endpoint.
» Read the findings
|
ADVERTISEMENT
Steroid Responsive Dermatoses & Severe Recalcitrant Nodular Acne
In this webinar, Mark Kaufmann, MD will discuss with you potential benefits of Promius Pharma's specialized distribution platform & an authorized generic version of one of its products. Sign up today!
 Read More.
|
|
Over the past few decades, efforts to slow the increase in cases of pediatric atopic dermatitis (AD), combined with a focus on the health benefits of breast-feeding, have led to the question of whether breast-feeding can reduce the risk of AD. » See the report results
|
ADVERTISEMENT
Are your patients really following their treatment?
Patient adherence is as critical as it is often elusive. In this complimentary webinar, learn how doctor-patient trust can be transformed into treatment success and cost savings.
 Click here for more
|
|
The Food and Drug Administration has granted 510(k) clearance to Cynosure, allowing it to market its PicoSure laser workstation for the treatment of wrinkles. » Read more details
|
|
In part 3 of our series, Drs. Elaine Siegfried and Steven Feldman discuss assessing adherence and intervening to encourage the best possible treatment outcomes. » Read the interview
|
|
|
Like
Tweet
